Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
09. August 2023 16:17 ET
|
Catalyst Pharmaceuticals, Inc.
Achieved Record Q2 2023 Total Net Revenues of $99.6 MillionAchieved FIRDAPSE® 2023 Second Quarter Net Revenues of $64.9 Million, a 22% Increase YOYAchieved 2023 Second Quarter GAAP EPS Diluted of...
Positive final results in stroke
03. Mai 2022 20:24 ET
|
Clinuvel Pharmaceuticals Limited
ASX: XETRA-DAX: Level 1 ADR:CUV UR9 CLVLY EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6)NIHSS1 scores improved in five...
CLINUVEL to Trial Innovative Drug in Stroke
27. Oktober 2020 18:50 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of...
AB Science dévoile les résultats de son étude de Phase IIB/III dans les formes progressives de la Sclérose en Plaques à l’occasion du plus grand congrès international sur la sclérose en plaques
14. September 2020 00:58 ET
|
AB Science
Paris, 14 septembre 2020, 7h00 Communiqué de Presse AB Science dévoile les résultats de son étude de Phase IIB/III dans les formes progressives de la Sclérose en Plaques à l’occasion du plus grand...
AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference
14. September 2020 00:58 ET
|
AB Science
Paris, September 14, 2020, 7am Press release AB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World's Largest Multiple Sclerosis Research Conference 50% of...
Arch Biopartners to Hold LSALT Peptide Webinar and Q&A Session August 18, 2020 at 11am EST
07. August 2020 11:34 ET
|
Arch Biopartners
TORONTO, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that it will host a webinar on August 18, 2020 at...
PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation
13. Juli 2020 03:38 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and SINGAPORE, July 13, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS today revealed PRÉNUMBRA®, the Company’s second afamelanotide product in development. PRÉNUMBRA® is a...
SCENESSE® to be Prescribed in China
23. April 2020 02:08 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and HANGZHOU, China, April 23, 2020 (GLOBE NEWSWIRE) -- Australian-based company CLINUVEL is launching SCENESSE® (afamelanotide 16mg) in the People’s Republic of China for the...
Innovative drug launched for rare, isolating, “light intolerance” disorder
16. April 2020 02:53 ET
|
Clinuvel Pharmaceuticals Limited
MELBOURNE, Australia and MENLO PARK, Calif., April 16, 2020 (GLOBE NEWSWIRE) -- Americans living with a rare genetic disorder that forces them to choose between self-isolation in the dark, or...
US FDA sets PDUFA date for SCENESSE®
10. Januar 2019 07:29 ET
|
Clinuvel Pharmaceuticals Limited
Executive summary New Drug Application submitted in accordance with section 505(b) of the Federal Food, Drug, and Cosmetic Act, filed in accordance with 21 CFR 314.101(a)Scientific exchange between...